Objective: To identify predictors of hypothalamic-pituitary-adrenal (HPA) axis recovery interval and severity of glucocorticoid withdrawal symptoms (GWS) in patients undergoing adrenalectomy for corticotropin-independent cortisol excess.
| INTRODUC TI ON
Adrenalectomy is the mainstay of treatment for patients with corticotropin (ACTH)-independent Cushing syndrome (CS) and achieves a cure rate of virtually 100%. Whilst overt adrenal CS is rare, biochemical abnormalities suggestive of mild autonomous cortisol excess (MACE, also known as "subclinical" CS) are much more common and are reported in at least 30% of patients with adrenal cortical adenomas.
1 Whilst patients with MACE lack the classic physical features of CS, they present with significantly higher rates of metabolic abnormalities that increase cardiovascular risk, morbidity and mortality, when compared to the general population. [2] [3] [4] [5] Postoperative adrenal insufficiency is the consequence of longstanding suppression of hypothalamic corticotropin-releasing hormone secretion, pituitary ACTH secretion and atrophy of normal adrenal cortex. Hypothalamic-pituitary-adrenal (HPA) axis suppression is present in all patients undergoing adrenalectomy for overt ACTH-independent CS and in approximately 50% of patients with MACE. 6, 7 Hence, following surgery most patients require glucocorticoid (GC) therapy for adrenal insufficiency replacement until the HPA axis recovers. However, despite GC therapy, patients often struggle with symptoms of fatigue, arthralgia, myalgia, decreased quality of life, depression and anxiety-symptoms attributed to a relative decrease in serum GC concentrations, so-called GC withdrawal symptoms (GWS).
GWS likely occur due to physical dependence on supraphysiological endogenous cortisol secretion prior to curative adrenalectomy.
When the source of cortisol excess is abruptly removed, behavioural and physiological changes in the body occur despite initiation of GC therapy. These changes manifest as a spectrum of signs and symptoms which collectively make up the GWS. 8 This syndrome is more frequently seen after discontinuation of supraphysiological GC therapy used to treat inflammatory conditions.
9
The duration of postoperative adrenal insufficiency is reported to vary widely, from weeks to years. 6 Biochemical and clinical variables, such as tumour size, degree of cortisol hypersecretion and/ or the presence of metabolic abnormalities, have been suggested as predictive factors for the development of postoperative adrenal insufficiency. 6, 7, 10, 11 However, it is unclear whether the degree of noted abnormalities influences the daily dose and duration of GC therapy, or the intensity of GWS after adrenalectomy. Current practice varies in regard to postoperative GC replacement-both in the GC regimens used and the different approaches to monitoring.
Moreover, whilst clinical guidelines recommend universal peri-and postoperative GC treatment, these provide only arbitrary advice on the GC dose and taper regimen.
6
Identification of baseline variables predictive of the postoperative course in patients with CS and MACE may help provide appropriate preoperative counselling, lead to more informed use of postoperative GC therapy and improve patients' quality of life. In this single-centre retrospective study, we address the scarcely studied and controversial topic of assessment and monitoring for HPA axis recovery based on our extensive clinical experience using a much more simplified assessment approach, and in opposition to the recent guidelines. Our study objectives include: (a) to determine the HPA axis recovery interval after curative adrenalectomy for adrenal CS and MACE and (b) to identify which baseline demographic, clinical and biochemical variables impact the duration and dose of the GC taper and the severity of GWS.
| ME THODS
This retrospective study was approved by the Mayo Clinic Institutional Review Board and included patients evaluated be- 
| Cortisol excess severity classification

| Biochemical criteria
We based our classification on the following: (a) increased endogenous cortisol production (24-hours urine free cortisol (UFC)
≥45 μg/24 hours or ≥1242 nmol/24 hours, 8AM serum cortisol >1.8 μg/dL or >50 nmol/L after 1-mg dexamethasone suppression test (DST) and midnight salivary cortisol ≥100 ng/dL or ≥2.8 nmol/ dL; (b) loss of circadian rhythm (absence of diurnal cortisol variation based on morning and afternoon serum cortisol concentrations); and (c) HPA axis suppression (ACTH ≤10 pg/mL or ≤2.2 pmol/L and dehydroepiandrosterone sulphate (DHEA-S) <50 μg/dL or <1.3 μmol/L).
For further details, see Table S1 in the Supporting Information.
| Clinical criteria
We took into account metabolic and/or physical findings related to cortisol excess (Table S2, 
| Diagnosis of postoperative adrenal insufficiency
| Postoperative recovery of adrenal function
We collected information on the duration and intensity of postoperative GC therapy and the severity of GWS until recovery of the HPA axis. If a GC other than hydrocortisone was used, we converted the doses into a hydrocortisone equivalent dose. 15 In patients treated with unilateral adrenalectomy, recovery of the HPA axis was considered to be achieved when an 8 AM serum cortisol was ≥10 μg/dL or ≥276 nmol/L at 24 hours after the last administered dose of GC.
| Classification of severity of GWS
GWS included nausea, arthralgia, myalgia, fatigue and headache. We classified GWS into the following categories:
| Mild
Symptoms did not limit activities of daily living (ADLs) or instrumental activities of daily living (IADLs). In this situation, patients were reassured and recommended to continue their GC taper as initially planned.
| Moderate
Symptoms somewhat limited IADLs, but not ADLs. In this situation, patients were advised to increase their GC dose to the previous dose at which they had no such symptoms.
| Severe
Symptoms significantly limited ADLs and IADLs. In this situation, patients were advised to double their dose of GC and then proceed with a slower taper.
| Adrenal crisis
Patients required hospital admission for intravenous GC administration due to hemodynamic instability and without evidence of another underlying aetiology. 
| Statistical analysis
| RE SULTS
| Baseline characteristics
Between 1 January 1998 and 1 June 2017, a total of 116 patients underwent adrenalectomy for ACTH-independent cortisol secretory autonomy and required postoperative GC therapy for adrenal insufficiency at the Mayo Clinic in Rochester. Twenty did not follow up at our institution. Thirteen patients had bilateral adrenalectomy and were therefore excluded. Our final cohort included 81 patients (79% female, 99% Caucasian) diagnosed with ACTHindependent cortisol excess with a median age of 52 years (IQR 42-62) (Table 1A) . Patients presented with either unilateral adenoma (n = 76, 93.8%) or macronodular disease (n = 5, 6.2%) (Table 1B) .
Patients with severe CS (n = 27, 33.3%) were younger at the time of diagnosis, endorsed a longer duration of symptoms prior to curative surgery and were more likely to be diagnosed nonincidentally (Table 1A) .
The most common metabolic abnormalities present at diagnosis included hypertension (76.5%) and weight gain (63.0%), followed by dyslipidemia (60.5%), type 2 diabetes mellitus and prediabetes (55.6%), and bone disease (37.0%) (Table 1C) . Patients reported a higher prevalence of weight gain in relation to the severity of CS (26.7% vs 70.8% vs 96.3% in MACE, moderate CS and severe CS, respectively, P < 0.0001). On physical examination, patients most commonly presented with supraclavicular and/or dorsocervical fat accumulation (42.0%), central obesity (39.5%) and rounding of the face with or without plethora (38.3%) ( Table 1D ). All standard-ofcare tests investigating cortisol excess demonstrated increasing degrees of abnormality in relation to CS severity (Table 1E) . Patients'
biochemical and clinical severity scores demonstrated a statistically significant positive correlation (R 2 = 0.33, P < 0.0001, Figure S1 ). Table 2 ).
TA B L E 1
The choice of GC depended on physician preference. Patients were followed for a median of 14.0 months (IQR 6.5-36.0) after adrenalectomy (Table 2) . At the time of manuscript preparation, 71 patients (87.7%) completed the GC taper.
Postoperative GC therapy was initiated at a median daily hydrocortisone dose of 40 mg (IQR 30-60) and lasted a median moderate CS and severe CS, respectively (P < 0.003, Figure 1B ).
The duration of GC therapy also correlated with the biochemical severity of CS (P < 0.0001, Figure 1C ). Subgroup analyses demonstrated that there was no significant difference in the median time to GC taper between patients with MACE and moderate CS, regardless of whether a clinical (P = 0.58) or biochemical (P = 0.16) classification of disease severity was used ( Figure 1B and 1C).
| Predictors of HPA axis recovery after adrenalectomy
| Univariate analysis
Univariate analysis showed that several demographic, clinical, imaging and biochemical variables predicted the duration of postoperative GC therapy (Table 3 ). The duration of cortisol excess signs and symptoms >12 months, younger age at the time of diagnosis, female sex, nonincidental discovery of adrenal tumour, adrenal mass diameter <40 mm and lower BMI were associated with a longer HPA axis recovery interval (Tables 3A and B, and Table S3 ). The type of GC used (hydrocortisone or prednisone) did not affect the duration of the taper (Table 3F and Figure S2 and S3).
In addition, certain signs of CS on physical examination were associated with the duration of postoperative GC use and included in order of strength of association: facial rounding and/or plethora, skin changes, objective myopathy, supraclavicular and/or dorsocervical fat pads, abdominal obesity and weight gain (Table 3D ). The number of physical examination signs suggestive of CS at presentation correlated with the duration of GC therapy (Table 3D ). However, we found no correlation between the number and degree of preoperative metabolic abnormalities and the duration of GC use (data not shown). Similarly, the number of abnormal biochemical tests consistent with cortisol excess correlated positively with the duration of GC therapy (Table 3E) . However, the only biochemical abnormalities were individually associated with postoperative GC therapy duration and included in order of strength of association: 24-hours UFC >45 μg/24 hours or >1242 nmol/24 hours; serum cortisol >10 μg/dL or >276 nmol/L after the 1-mg DST; ACTH ≤10 pg/mL or ≤2.2 pmol/L; and loss of circadian rhythm. DHEA-S suppression and elevated midnight salivary cortisol were not associated with the duration of GC use (data not shown). Table 4 ). Although the severity of CS did not significantly correlate with the incidence of GWS (R 2 = 0.05, P = 0.11, Figure 2A ), patients with severe CS had a significantly higher incidence of GWS events compared to patients with MACE (P = 0.04, Figure 2A ). Although we observed a trend for a higher incidence of mild, moderate and severe
| Multivariable analysis
| Glucocorticoid withdrawal events
GWS as well as hospitalizations for adrenal crisis in patients with
severe CS, this did not reach statistical significance ( Figure 2B ).
GWS events were most frequent when 8 AM serum cortisol 24 hours off GC was <5 μg/dL (<138 nmol/L; Figure 2C ). However, patients still reported GC withdrawal symptoms even when 8 AM serum cortisol 24 hours off GC was between 5 and 9.9 μg/ dL(138-275 nmol/L; Figure 2C ,D), although the majority of events in this group were mild (31/53, 58.5%, data not shown). Patients reported no GWS events at the time when 8AM serum cortisol 24 hours off GC was ≥10 μg/dL (≥276 nmol/L), our biochemical definition of HPA recovery and the time when patients would stop physiological GC replacement therapy. There was no correlation between the incidence of GWS and demographic, clinical or imaging variables (data not shown). The type of GC used (hydrocortisone or prednisone) did not affect the incidence of GWS (Table   S4 ).
| D ISCUSS I ON
In this study, we hypothesized that baseline demographic, clinical and biochemical variables predict the HPA axis recovery interval and the severity of GWS in patients treated with adrenalectomy for ACTH-independent cortisol excess.
We observed that the median time to HPA axis recovery was We found that metabolic complications recognized to be associated with subtle cortisol excess, such as low bone mineral density, hypertension, dyslipidemia and type 2 diabetes, 20 did not influence the duration of the postoperative GC taper. Whilst patients who reported weight gain prior to curative surgery experienced a longer HPA axis recovery interval, these patients had overall a lower BMI. Possible explanations are that metabolic abnormalities in CS are common, but not specific, 21, 22 as well as different sensitivities of various organs to cortisol excess. 23 In other words, mild cortisol excess may be sufficient to affect bone and fat metabolism, but not enough to affect the severity of HPA axis suppression and then recovery.
In our study, we demonstrated that GWS after adrenalectomy for ACTH-independent cortisol excess were frequent. Whilst GWS events were most common at the time when 8 AM serum cortisol 24 hours off GC was <5 mcg/dL (<138 nmol/L), patients experienced Continuous data are summarized as median and interquartile ranges. Categorical data are presented as frequencies and percentages. All P-values <0.05 were considered significant. CS, Cushing syndrome; GC, glucocorticoid; IV, intravenous; MACE, mild autonomous cortisol excess.
F I G U R E 1 Postoperative glucocorticoid therapy duration for all patients (n = 81) and based on clinical and the biochemical severities of cortisol excess. Data are summarized as median and interquartile ranges. All P-values <0.05 were considered significant. Abbreviations used: CS, Cushing syndrome; IQR, interquartile range; MACE, mild autonomous cortisol excess GWS were encountered even when 8 AM serum cortisol was within "normal range" (>7 μg/dL or >193 nmol/L, the cut-off used at our institution). GWS occurs due to a relative decrease in cortisol concentrations after surgical cure and consists not only of physical signs and symptoms, but also of psychiatric symptoms (such as depression and anxiety), which affect recovery and overall quality of life. 24, 25 Patients with severe CS, but not those with moderate CS, had a higher incidence and intensity of GWS when compared to patients with MACE.
We found that the severity of CS is the only predictor of the number of GC withdrawal events after adrenalectomy. We found no other demographic, clinical or biochemical independent predictors of postoperative GWS. It is important to note that whilst GWS were common, most were mild and required no intervention: only 40.8% of our patients with severe CS reported mild GWS not requiring intervention and 40% had symptoms which required an increase in GC dose. In another study of only eight patients with overt CS, all complained of mild GWS and only 50% had signs or symptoms (severe weakness, dizziness, failure to thrive and/or hypotension) requiring an increase in GC dose. 26 In contradiction to a published report, the incidence and severity of GWS were not affected by the type of GC used.
27
Our study has several limitations and strengths. Strengths of the study include a high level of detail in regard to preoperative symptoms, physical features of CS and GWS. In addition, the GC taper at our institution is usually performed based on patients' symptoms with frequent biochemical reassessments once the GC taper reaches a physiological replacement dose. This allowed a more accurate as- 
TA B L E 3 (Continued)
postoperative characteristics except for the prevalence of central obesity and serum DHEA-S concentrations ( 
TA B L E 4 (Continued)
≥10 μg/dL (≥276 nmol/L). On the other hand, patients with moderate CS and MACE are more likely to tolerate a more aggressive GC taper and should have an earlier evaluation for HPA axis recovery. GWS are common after adrenalectomy for ACTH-independent hypercortisolism. The frequency of reported GWS events correlated with the 8AM serum cortisol concentration 24 hours off GC, as no GWS events were reported at serum cortisol concentrations ≥10 mcg/dL.
Few events require intervention; thus, we recommend that in addition to education on adrenal insufficiency, patients are counselled on management of GWS. 
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